ReviewAmerican journal of translational research2025
Rituximab plus chemotherapy for pediatric mature B-cell non-Hodgkin's lymphoma: a systematic review and meta-analysis.
Review in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo conduct a systematic review and meta-analysis evaluating the efficacy and safety of rituximab combined with chemotherapy for the treatment of mature B-cell non-Hodgkin's lymphoma (NHL) in children and adolescents.
methodsA comprehensive search of PubMed, Embase, the Cochrane Library, and Web of Science was performed to identify relevant studies published up to October 2024. Eligible studies included those involving patients aged 0-15 years diagnosed with mature B-cell NHL. Data were extracted on event-free survival (EFS), overall survival (OS), complete remission rate (CRR), adverse events, immune reconstitution (IgG levels), and recurrence rates. Meta-analyses were conducted using RevMan 5.0.
resultsA total of 11 studies comprising 1,522 participants were included. The addition of rituximab to chemotherapy significantly improved EFS (hazard ratio [HR] = 0.40, 95% confidence interval [CI]: 0.36-0.45,
conclusionThe addition of rituximab to chemotherapy significantly improved EFS, OS, and CRR in children and adolescents with mature B-cell NHL. Despite an increased risk of toxicity, the survival and remission benefits support the use of rituximab in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.